Hanall Biopharma financials at a glance

+ Portfolio

The revenue of Hanall Biopharma is reported as 134.90984 billion Won in the fiscal year 2023. The earnings were 69 Won per share in 2023, which was 1280 higher than 2022. And about 6.61287 billion Won are reported as free cash flow in the financials of Hanall Biopharma 2023. No dividends were paid to the shareholders of the Hanall Biopharma stock KOSE:A009420 in the financial year 2023.

₩134.91B

Revenue

₩69.00

Earnings Per Share

55.62%

Gross Margin %

₩6.03B

Free Cash Flow

Revenue

134,909.84

Earnings Per Share

69.00

Gross Margin %

55.62

Free Cash Flow

6,033.33

Financials

Year	Year	TTM	2023	2022	2021	2020	2019	2018	2017	2015	2012
Rev.	Revenue	N/A	₩134.91B	₩110.00B	₩101.59B	₩88.60B	₩108.45B	₩91.84B	₩84.23B	₩80.02B	₩0.00M
GM %	Gross Margin %	58.57%	55.62%	56.25%	59.29%	57.08%	57.80%	53.27%	50.58%	45.62%	46.37%
OM	Operating Margin	5.22%	1.29%	1.37%	9.94%	6.70%	15.76%	5.96%	4.20%	-5.35%	-4.03%
EPS	Earnings Per Share	₩119.33	₩69.00	₩5.00	₩174.00	₩386.00	₩375.00	₩64.00	₩114.00	₩10.00	₩-79.00
Div.	Dividends	N/A	₩0.00	₩0.00	₩0.00	₩0.00	₩0.00	₩0.00	₩0.00	₩0.00	₩0.00
PR %	Payout Ratio %	0	0	0	0	0	0	0	0	0	0
Sha.	Shares	N/AM	50.69M	50.69M	51.21M	51.18M	51.18M	51.18M	51.18M	50M	40.34M
OCF	Operating Cash Flow	N/A	₩9.03B	₩25.20B	₩839.87M	₩929.29M	₩20.49B	₩-2,994.39M	₩0.00M	₩0.00M	₩0.00M
FCF	Free Cash Flow	N/A	₩6.03B	₩22.37B	₩-3,766.03M	₩-1,633.03M	₩20.28B	₩-4,913.31M	₩0.00M	₩0.00M	₩0.00M
FCFS	Free Cash Flow Per Share	₩402.76	₩403.32	₩344.92	₩-,159.41	₩-,126.23	₩238.68	₩-96.01	₩783.05	₩-81.68	₩-,129.61

Hanall Biopharma financials at a glance

Financials

Discover